Nitto Denko, Quark Pharma Collaborate To Jointly Develop siRNA Anti-fibrotic Drug
Nitto Denko and Quark Pharma are expected to develop siRNA drugs using Quark’s RNAi technologies and new structures providing freedom to operate in the siRNA intellectual property space
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.